Histone Deacetylase 6 (HDAC6) As A Therapeutic Target in Chronic Lymphocytic Leukemia
Poster Dec 13, 2017
Kamira K. Maharaj, John Powers, Susan L. Deng, Alex Achille, Mibel Pabon-Saldana, Renee Fonseca, Steven N. Quayle, Simon S. Jones, Eva Sahakian and Javier Pinilla-Ibarz
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the western world and is characterized by an accumulation of CD5+ B cells in circulation and lymphoid tissue. There is a need to identify novel therapies for CLL patients due to prevalence of partial responses and relapsed/refractory disease. In CLL, an immunosuppressive phenotype enables the malignant B cell to evade immune detection, leading to immune suppression. In recent years, epigenetic changes prompted by proteins known as histone deacetylases (HDACs) have gained special attention predominantly because of their active role in the regulation of pathogenesis and immune-related pathways in CLL; though the precise mechanism by which these regulatory events take place has yet to be elucidated. In addition to the well-recognized role of histone deacetylase inhibitors (HDACi) in the control of cell cycle and apoptosis, HDACi have a potential role in modulating the immunobiology of CLL. HDACs may therefore represent viable targets to develop new immunomodulating therapies for CLL.
In this study, we aimed to investigate the role of histone deacetylase 6 (HDAC6) in immunobiology of CLL and determine how HDAC6 may regulate malignant B cell survival pathways. Further, we aimed to determine efficacy of HDAC6 inhibition in a CLL murine model.
Collectively our data confirms the importance of HDAC6 to CLL progression. We have found that HDAC6 inhibition regulates CLL immunobiology to deter tumor cell immune evasion mechanisms and reinvigorate a beneficial immune response against CLL disease. Results from our preclinical CLL models suggest that HDAC6 represents a viable therapeutic target in CLL. This target may be developed with the intention to treat relapsed/refractory CLL patients or weaker, aged patients.
Identification of genes involved in cell cycle regulation using arrayed synthetic CRISPR RNA libraries in a multiparameter high-content assayPoster
Gene knockout using CRISPR-Cas9 has dramatically transformed biological research and has been rapidly applied to loss-of-function screening primarily using pooled lentiviral sgRNA libraries. A synthetic CRISPR RNA (crRNA) approach is amenable to screening in arrayed, well-by-well fashion and expands the types of phenotypic readouts that can be used, including high-content and morphology-based assays.READ MORE
Nitrogen metabolism in Mycobacterium tuberculosis: a systems-based approachPoster
Previous studies suggested that Mycobacterium tuberculosis obtains nitrogen from a diverse range of intracellular nutrients including amino acids. Here, we use a novel system’s based three-pronged approach to define pathways for uptake and assimilation of nitrogen.READ MORE
Cerebral Malaria Insights: Pathogenesis, Host Parasite Interactions including Host ResistancePoster
Cerebral malaria is a dreadful disease transmitted by mosquito. The major preventive approach is focused more in vector control than development of anti-malarial drug. The purpose of this presentation is to analyze different aspects of disease manifestations including clinical symptoms and pathogenesis in the context of mosquito borne infections in different geographical regions of the world.READ MORE
Comments | 0 ADD COMMENT
2nd International Conference and Exhibition on Nanomedicine and Drug Delivery
May 21 - May 23, 2018